Evidence map›Paper›PMID 37959412›Full record

ArticleJournal of clinical medicine2023

Exploring the Potential of the Corpus Callosum Area as a Predictive Marker for Impaired Information Processing in Multiple Sclerosis.

Shun Akaike, Tomoko Okamoto, Ryoji Kurosawa, Nozomi Onodera, Youwei Lin, Wakiro Sato, Takashi Yamamura, Yuji Takahashi

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Shun AkaikeDepartment of Neurology, National Center of Neurology and Psychiatry, Tokyo 187-8551, Japan.
Tomoko OkamotoDepartment of Neurology, National Center of Neurology and Psychiatry, Tokyo 187-8551, Japan.ORCID 0000-0002-0983-3346
Ryoji KurosawaDepartment of Neurology, National Center of Neurology and Psychiatry, Tokyo 187-8551, Japan.
Nozomi OnoderaDepartment of Neurology, National Center of Neurology and Psychiatry, Tokyo 187-8551, Japan.
Youwei LinDepartment of Neurology, National Center of Neurology and Psychiatry, Tokyo 187-8551, Japan.
Wakiro SatoDepartment of Immunology, National Center of Neurology and Psychiatry, Tokyo 187-8551, Japan.ORCID 0000-0003-4082-3557
Takashi YamamuraDepartment of Immunology, National Center of Neurology and Psychiatry, Tokyo 187-8551, Japan.
Yuji TakahashiDepartment of Neurology, National Center of Neurology and Psychiatry, Tokyo 187-8551, Japan.
National Center of Neurology and Psychiatry · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early cognitive impairment (CI) detection is crucial in multiple sclerosis (MS). However, it can progress silently regardless of relapse activity and reach an advanced stage. We aimed to determine whether the corpus callosum area (CCA) is a sensitive and feasible marker for CI in MS compared to other neuroimaging markers. We assessed cognitive function in 77 MS patients using the Symbol Digit Modalities Test, Paced Auditory Serial Additions Task, Wechsler Adult Intelligence Scale-IV, and Wechsler Memory Scale-Revised. The neuroimaging markers included manually measured CCA, two diffusion tensor imaging markers, and nine volumetric measurements. Apart from volumes of the hippocampus and cerebellum, ten markers showed a significant correlation with all neuropsychological tests and significant differences between the groups. The normalized CCA demonstrated a moderate-to-strong correlation with all neuropsychological tests and successfully differentiated between the CI and cognitively normal groups with 80% sensitivity and 83% specificity. The marker had a large area under the curve and a high Youden index (0.82 and 0.63, respectively) and comparability with established cognitive markers. Therefore, the normalized CCA may serve as a reliable marker for CI in MS and can be easily implemented in clinical practice, providing a supportive diagnostic tool for CI in MS.

Indexed as

cognitive impairmentmagnetic resonance imagingmultiple sclerosis

Identifiers

PMID37959412
PMCPMC10647459
OpenAlexW4388408455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.